254 related articles for article (PubMed ID: 32236485)
1. Cathelicidin-inspired antimicrobial peptides as novel antifungal compounds.
van Eijk M; Boerefijn S; Cen L; Rosa M; Morren MJH; van der Ent CK; Kraak B; Dijksterhuis J; Valdes ID; Haagsman HP; de Cock H
Med Mycol; 2020 Nov; 58(8):1073-1084. PubMed ID: 32236485
[TBL] [Abstract][Full Text] [Related]
2. PepBiotics, novel cathelicidin-inspired antimicrobials to fight pulmonary bacterial infections.
van Eijk M; van Dijk A; van der Ent CK; Arets HGM; Breukink E; van Os N; Adrichem R; van der Water S; Lino Gómez R; Kristensen M; Hessing M; Jekhmane S; Weingarth M; Veldhuizen RAW; Veldhuizen EJA; Haagsman HP
Biochim Biophys Acta Gen Subj; 2021 Sep; 1865(9):129951. PubMed ID: 34147544
[TBL] [Abstract][Full Text] [Related]
3. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
Jensen RH
Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
[TBL] [Abstract][Full Text] [Related]
4. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens.
Uchida K; Nishiyama Y; Yokota N; Yamaguchi H
J Antibiot (Tokyo); 2000 Oct; 53(10):1175-81. PubMed ID: 11132964
[TBL] [Abstract][Full Text] [Related]
5. Fungicidal activity of five cathelicidin peptides against clinically isolated yeasts.
Benincasa M; Scocchi M; Pacor S; Tossi A; Nobili D; Basaglia G; Busetti M; Gennaro R
J Antimicrob Chemother; 2006 Nov; 58(5):950-9. PubMed ID: 17023499
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
Fritsche TR; Rhomberg PR; Sader HS; Jones RN
Antimicrob Agents Chemother; 2008 Mar; 52(3):1187-9. PubMed ID: 18180345
[TBL] [Abstract][Full Text] [Related]
7. Antifungal activity of cathelicidin peptides against planktonic and biofilm cultures of Candida species isolated from vaginal infections.
Scarsini M; Tomasinsig L; Arzese A; D'Este F; Oro D; Skerlavaj B
Peptides; 2015 Sep; 71():211-21. PubMed ID: 26238597
[TBL] [Abstract][Full Text] [Related]
8. CYP51 Paralogue Structure Is Associated with Intrinsic Azole Resistance in Fungi.
Van Rhijn N; Bromley M; Richardson M; Bowyer P
mBio; 2021 Oct; 12(5):e0194521. PubMed ID: 34607450
[TBL] [Abstract][Full Text] [Related]
9. Small molecules restore azole activity against drug-tolerant and drug-resistant
Alabi PE; Gautier C; Murphy TP; Gu X; Lepas M; Aimanianda V; Sello JK; Ene IV
mBio; 2023 Aug; 14(4):e0047923. PubMed ID: 37326546
[TBL] [Abstract][Full Text] [Related]
10. Alexidine Dihydrochloride Has Broad-Spectrum Activities against Diverse Fungal Pathogens.
Mamouei Z; Alqarihi A; Singh S; Xu S; Mansour MK; Ibrahim AS; Uppuluri P
mSphere; 2018 Oct; 3(5):. PubMed ID: 30381356
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of posaconazole and comparators versus opportunistic filamentous fungal pathogens globally collected during 8 years.
Pfaller MA; Carvalhaes CG; Messer SA; Rhomberg PR; Castanheira M
Diagn Microbiol Infect Dis; 2021 Nov; 101(3):115473. PubMed ID: 34352433
[TBL] [Abstract][Full Text] [Related]
12.
Sun Y; Tan L; Yao Z; Gao L; Yang J; Zeng T
Microbiol Spectr; 2022 Feb; 10(1):e0200721. PubMed ID: 35019705
[TBL] [Abstract][Full Text] [Related]
13. New and Promising Chemotherapeutics for Emerging Infections Involving Drug-resistant Non-albicans Candida Species.
Silva LN; de Mello TP; de Souza Ramos L; Branquinha MH; Dos Santos ALS
Curr Top Med Chem; 2019; 19(28):2527-2553. PubMed ID: 31654512
[TBL] [Abstract][Full Text] [Related]
14. Anti-fungal activity of Ctn[15-34], the C-terminal peptide fragment of crotalicidin, a rattlesnake venom gland cathelicidin.
Cavalcante CS; Falcão CB; Fontenelle RO; Andreu D; Rádis-Baptista G
J Antibiot (Tokyo); 2017 Mar; 70(3):231-237. PubMed ID: 27876749
[TBL] [Abstract][Full Text] [Related]
15. In vitro antifungal activity of posaconazole against various pathogenic fungi.
Uchida K; Yokota N; Yamaguchi H
Int J Antimicrob Agents; 2001 Aug; 18(2):167-72. PubMed ID: 11516940
[TBL] [Abstract][Full Text] [Related]
16. Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus.
Wiederhold NP; Patterson HP; Tran BH; Yates CM; Schotzinger RJ; Garvey EP
J Antimicrob Chemother; 2018 Feb; 73(2):404-408. PubMed ID: 29190379
[TBL] [Abstract][Full Text] [Related]
17. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
Lass-Flörl C; Mayr A; Perkhofer S; Hinterberger G; Hausdorfer J; Speth C; Fille M
Antimicrob Agents Chemother; 2008 Oct; 52(10):3637-41. PubMed ID: 18694949
[TBL] [Abstract][Full Text] [Related]
18.
Colley T; Sehra G; Chowdhary A; Alanio A; Kelly SL; Kizawa Y; Armstrong-James D; Fisher MC; Warrilow AGS; Parker JE; Kelly DE; Kimura G; Nishimoto Y; Sunose M; Onions S; Crepin D; Lagasse F; Crittall M; Shannon J; McConville M; King-Underwood J; Naylor A; Bretagne S; Murray J; Ito K; Strong P; Rapeport G
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29439966
[TBL] [Abstract][Full Text] [Related]
19. Synergistic Antifungal Effect of a Combination of Iron Deficiency and Calcium Supplementation.
Ye J; Wang Y; Li X; Wan Q; Zhang Y; Lu L
Microbiol Spectr; 2022 Jun; 10(3):e0112122. PubMed ID: 35674440
[TBL] [Abstract][Full Text] [Related]
20. Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012).
Pfaller MA; Messer SA; Jones RN; Castanheira M
J Antibiot (Tokyo); 2015 Sep; 68(9):556-61. PubMed ID: 25899126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
